Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

which suppresses the immune system from fighting cancer cells. And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Pfizer bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 billion, as well as royalties if the treatment is approved.

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

SWEATING THE MAHA REPORT — A report expected today from Robert F. Kennedy Jr. on childhood chronic diseases could spark ...